Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.

被引：1
|
作者：
Harbeck, Nadia
Nitz, Ulrike
Christgen, Matthias
Kates, Ronald E.
Braun, Michael Wilhelm
Kummel, Sherko
Schumacher, Claudia
Potenberg, Jochem
Malter, Wolfram
Augustin, Doris
Aktas, Bahriye
Forstbauer, Helmut
Tio, Joke
Kleine-Tebbe, Anke
Liedtke, Cornelia
de Haas, Sanne
Deurloo, Regula
Wuerstlein, Rachel
Kreipe, Hans Heinrich
Gluz, Oleg
机构：
[1] Univ Munchen LMU, Brustzentrum, Munich, Germany
[2] Evangel Hosp Bethesda, Breast Canc Niederrhein, Monchengladbach, Germany
[3] Hannover Med Sch, Hannover, Germany
[4] West German Study Grp, Monchengladbach, Germany
[5] Rotkreuzklinikum, Munich, Germany
[6] Kliniken Essen Mitte, Essen, Germany
[7] St Elisabeth Hosp Koln Hohenlind, Cologne, Germany
[8] Waldkrankenhaus Spandau, Dept Hematol, Berlin, Germany
[9] Univ Hosp Cologne, Dept Obstet & Gynecol, Cologne, Germany
[10] Klinikum Deggendorf, Deggendorf, Germany
[11] Univ Hosp Leipzig, Univ Hosp Essen, Essen, Germany
[12] Practice Network Hematol Oncol, Troisdorf, Germany
[13] Univ Hosp Muenster, Dept Gynecol & Obstet, Munster, Germany
[14] DRK Kliniken Berlin Kopenick, Berlin, Germany
[15] Charite Univ Med Berlin, Berlin, Germany
[16] F Hoffmann La Roche Ltd, Basel, Switzerland
[17] Ludwig Maximilians Univ Munchen, Munich, Germany
[18] Breast Ctr Niederrhein, Monchengladbach, Germany
[19] Univ Clin Cologne, Monchengladbach, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
572
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer
    Myers, Andrea P.
    Konstantinopoulos, Panagiotis A.
    Barry, William T.
    Luo, Weixiu
    Broaddus, Russell R.
    Makker, Vicky
    Drapkin, Ronny
    Liu, Joyce
    Doyle, Austin
    Horowitz, Neil S.
    Meric-Bernstam, Funda
    Birrer, Michael
    Aghajanian, Carol
    Coleman, Robert L.
    Mills, Gordon B.
    Cantley, Lewis C.
    Matulonis, Ursula A.
    Westin, Shannon N.
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (02) : 413 - 422
  • [32] Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Jhaveri, Komal
    Juric, Dejan
    Varga, Andrea
    Turner, Nicolas
    Schmid, Peter
    Saura, Cristina
    Oliveira, Mafalda
    Krop, Ian E.
    Kalinsky, Kevin
    Italiano, Antoine
    Hamilton, Erika
    Gambardella, Valentina
    Cervantes, Andres
    Bedard, Philippe L.
    Liu, Bonnie P.
    Chen, Jessica W.
    Aimi, Junko
    Royer-Joo, Stephanie
    Schutzman, Jennifer L.
    Hutchinson, Katherine E.
    CANCER RESEARCH, 2021, 81 (04)
  • [33] De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel (vol 28, pg 2768, 2017)
    Nitz, U. A. D.
    Gluz, O.
    Christgen, M.
    Grischke, E. -M.
    Augustin, D.
    Kuemmel, S.
    Braun, M.
    Potenberg, J.
    Kohls, A.
    Krauss, K.
    Stefek, A.
    Schumacher, C.
    Forstbauer, H.
    Reimer, T.
    Fischer, H.
    Liedtke, C.
    Wuerstlein, R.
    Schumacher, J.
    Kates, R.
    Kreipe, H.
    Harbeck, N.
    WSG-ADAPT Investigators
    ANNALS OF ONCOLOGY, 2022, 33 (03) : 355 - 355
  • [34] Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2-Breast Cancer
    Venetis, Konstantinos
    Pepe, Francesco
    Munzone, Elisabetta
    Sajjadi, Elham
    Russo, Gianluca
    Pisapia, Pasquale
    Ivanova, Mariia
    Bonizzi, Giuseppina
    Vacirca, Davide
    Rappa, Alessandra
    Ranghiero, Alberto
    Taormina, Sergio Vincenzo
    Viale, Giuseppe
    Troncone, Giancarlo
    Barberis, Massimo
    Guerini-Rocco, Elena
    Malapelle, Umberto
    Fusco, Nicola
    CELLS, 2022, 11 (22)
  • [35] A large study of PIK3CA mutations in the community setting identifies varying degree of mutation positivity rates across age groups in advanced HR+, HER2-breast cancer patients using an FDA RT-PCR cleared test
    Chan, Alex C.
    Weiss, Lawrence M.
    Bender, Ryan
    CANCER RESEARCH, 2020, 80 (04)
  • [36] Efficacy results based on PIK3CA status in BELLE-3: A Phase 3 study of buparlisib (BKM120) + fulvestrant in postmenopausal women with aromatase inhibitor-treated, HR+/HER2-ABC after progression on an mTOR inhibitor
    O'Regan, Ruth
    Arteaga, Carlos L.
    Bachelot, Thomas
    Ciruelos, Eva
    Lonning, Per E.
    Sankaran, Banu
    Wang, Ying A.
    Scheuer, Nicolas
    Sellami, Dalila
    Hirawat, Samit
    Di Leo, Angelo
    CANCER RESEARCH, 2017, 77
  • [37] Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2-trial
    Harbeck, Nadia
    Gluz, Oleg
    Kuemmel, Sherko
    Christgen, Matthias
    Braun, Michael
    Aktas, Bahriye
    Luedtke-Heckenkamp, Kerstin
    Forstbauer, Helmut
    Grischke, Eva-Maria
    Schumacher, Claudia
    Darsow, Maren
    Krauss, Katja
    Nuding, Benno
    Thill, Marc
    Potenberg, Jochem
    Uleer, Christoph
    Warm, Mathias
    Fischer, Hans H.
    Malter, Wolfram
    Hauptmann, Michael
    Kates, Ronald
    Graeser, Monika
    Wuerstlein, Rachel
    Shak, Steve
    Baehner, Rick
    Kreipe, Hans
    Nitz, Ulrike
    CANCER RESEARCH, 2021, 81 (04)
  • [38] PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2-advanced breast cancer (BC): First results from the randomized, phase Ill BELLE-2 trial
    Baselga, J.
    Im, S-A
    Iwata, H.
    Clemons, M.
    Ito, Y.
    Awada, A.
    Chia, S.
    Jagiello-Gruszfeld, A.
    Pistilli, B.
    Tseng, L-M
    Hurvitz, S.
    Masuda, N.
    Cortes, J.
    De Laurentiis, M.
    Arteaga, C. L.
    Jiang, Z.
    Jonat, W.
    Hachemi, S.
    Le Mouhaer, S.
    Di Tomaso, E.
    Urban, P.
    Massacesi, C.
    Campone, M.
    CANCER RESEARCH, 2016, 76
  • [39] Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2-metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial
    Gustavo, Federico
    Todo, Rojo
    Meier, Lara
    Martinez, Maria Teresa
    Lopez, Maria Esteban
    Paris, Lorena
    O'Connor, Miriam
    Merino, Luis De la Cruz
    Santaballa, Ana
    Martinez-Janez, Noelia
    Anton, Fernando Moreno
    Fernandez, Isaura
    Keane, Maccon
    Garcia-Palomo, Andres
    Starus, Anna
    Portela, Marta
    Herranz, Jesus
    Caballero, Rosalia
    Jones, Frederick
    Albanell, Joan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer
    Zagami, Paola
    Fernandez-Martinez, Aranzazu
    Rashid, Naim U.
    Hoadley, Katherine A.
    Spears, Patricia A.
    Curigliano, Giuseppe
    Perou, Charles M.
    Carey, Lisa A.
    JAMA NETWORK OPEN, 2023, 6 (12) : E2348814
12345